Economic consequences of surfactant therapy.
Eidelman
A I
AI
Department of Neonatology, Shaare Zedek Medical Center, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal / Q000191:economics*; D011663:Pulmonary Surfactants / Q000191:economics* / Q000627:therapeutic use; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000191:economics / Q000401:mortality
D011663:Pulmonary Surfactants